Indian Journal of Hematology & Blood Transfusion · Aug 24, 2026
Pathophysiology of Acquired Aplastic Anaemia
By Singh G, Purohit A, Tejwani N
Acquired aplastic anaemia (aAA) is a rare but potentially life-threatening bone marrow failure syndrome defined by peripheral pancytopenia and hypocellular marrow. It arises from the interplay of multiple pathogenic processes: immune-mediated destruction of hematopoietic stem and progenitor cells (HSPCs), intrinsic stem cell vulnerabilities, telomere dysregulation, clonal haematopoiesis, paroxysmal nocturnal haemoglobinuria (PNH) clones, and disruption of the bone marrow microenvironment. The immune model centres on autoreactive cytotoxic T cells producing myelosuppressive cytokines such as interferon-γ and tumour necrosis factor-α, driving apoptosis and arresting proliferation. Yet, this immune injury occurs alongside genetic instability, microenvironmental collapse, and-in older adults-chronic, low-grade inflammation ("inflammaging") that further depletes stem cell reserves. Recent genomic advances have revealed a spectrum of somatic mutations with variable impacts on prognosis and therapeutic response, while niche biology studies underscore the role of stromal, vascular, and osteoblastic health in marrow recovery. The frequent detection of PNH-type clones illustrates how immune selection shapes the marrow ecosystem. In this narrative synthesis of the published literature, we integrate classical concepts with contemporary findings from immunology, molecular genetics, and microenvironmental research, highlighting unresolved controversies and their clinical implications. Rather than proposing new experimental data, we draw on this evidence base to argue that aAA is better conceptualised as a dynamic, multi-pathway network disorder than as a single unifying mechanism - a framework in which immune, genetic, and tissue-level processes interact to determine disease onset, evolution, and treatment outcome.